CTLA4 and neoplasm: While checkpoint blockade using anti-CTLA-4 ipilimumab, and anti-PD1 antibodies nivolumab or pembrolizumab for DMG has failed as a monotherapy,29 enhancement of CAR T cell immunotherapy in combination with checkpoint blockade may improve anti-tumor efficacy.